Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices
2013-05
Loading...
View/Download File
Persistent link to this item
Statistics
View StatisticsJournal Title
Journal ISSN
Volume Title
Title
Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices
Authors
Published Date
2013-05
Publisher
Type
Thesis or Dissertation
Abstract
Dabigatran and rivaroxaban are two new oral anticoagulants that have been recently approved as alternatives to warfarin. Clinical trials have shown non-inferiority of the new oral anticoagulants to warfarin for anti-thrombotic effects with equal to decreased bleeding risk. Unfortunately no standard method to assess the level of anticoagulation or reverse the effects of dabigatran or rivaroxaban is available. Current recommended management of bleeding patients taking dabigatran or rivaroxaban is based on expert opinion. To gain information from experience of physicians who have managed hemorrhaging patients, U.S. non-malignant hematologists were surveyed with a 31% response rate. In total, 43 cases of dabigatran associated hemorrhage and 5 cases of rivaroxaban associated bleeding were reported. Factor concentrates were used in 9 cases of dabigatran hemorrhage with perceived effectiveness ranging from 50-80%. A national registry is needed to track management of hemorrhages until antidotes become available.
Keywords
Description
University of Minnesota M.S. thesis. Major: Clinical Research. May 2013. Advisor: Mark T. Reding. 1 computer file (PDF); vi, 36 pages.
Related to
Replaces
License
Series/Report Number
Funding information
Isbn identifier
Doi identifier
Previously Published Citation
Suggested citation
Baumann Kreuziger, Lisa M.. (2013). Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/156571.
Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.